Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1873-1879

  Tsui, Florence W L ^a,b   Tsui, Hing Wo ^a   Heras, Facundo Las ^c   Pritzker, Kenneth P H ^d   Inman, Robert D ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; NOGGIN N54; PEPTIDE; PROTEIN A; PROTEIN G; SCLEROSTIN S146; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; CARRIER PROTEIN; GENETIC MARKER; GLYCOPROTEIN; IMMUNOGLOBULIN G; NOGGIN PROTEIN; SOST PROTEIN, HUMAN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKYLOSING SPONDYLITIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; BACKACHE; BINDING ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOPRECIPITATION; INFLAMMATORY BOWEL DISEASE; MALE; MECHANICAL BACK PAIN; MOUSE; NONHUMAN; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; ANIMAL; BLOOD; CASE CONTROL STUDY; GENETIC MARKER; IMMUNOLOGY; MOLECULAR MIMICRY; SPONDYLITIS, ANKYLOSING;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; GENETIC MARKERS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MICE; MOLECULAR MIMICRY; SPONDYLITIS, ANKYLOSING;

EID: 84906991087     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203630     Document Type: Article

References (31)

1. van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
2. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-6.
3. Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnosis axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
4. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
5. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62.
6. Las Heras F, Pritzker KPH, So A, et al. Aberrant chondrocyte hypertrophy and activation of ß-catenin signalling precede joint ankylosis in ank/ank mice. J Rheumatol 2012;39:583-93.
7. Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
8. Jacques P, Elewaut D, Mielants H. Interaction between gut inflammation and arthritis/spondylitis. Curr Opin Rheumatol 2010;22:368-74.
9. van Praet L, van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414-7.
10. Groppe J, Greenwald J, Wiater E, et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002;420:636-42.
11. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signalling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
12. Winkler DG, Yu C, Geoghegan JC, et al. Noggin and Sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279:36293-8.
13. Brewerton DA, Hart FD, Nicholls M, et al. Ankylosing spondylitis and HL-A27. Lancet 1973;1:904-7.
14. Schlosstein L, Terasake PI, Bluestone R, et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. New Engl J Med 1973;288:704-6.
15. Wellcome Trust Case Control Consortium. Association scan of 14, 5000 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
16. Danoy P, Pryce K, Hadler J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 2010;6:e1001195.
17. Laukens D, Georges M, Libioulle C, et al. Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. PLoS One 2010;5:e13795.
18. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20:451-71.
19. Pal B. Ankylosing spondylitis, a seronegative spondarthritis. Practitioner 1987;231:785-93.
20. Wright C, Sibani S, Trudgian D, et al. Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics 2012;11:M9.00384.
21. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012;97:148-52.
22. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
23. Brakenholl LK, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management. Gut 2011;60:1426-35.
24. Saad CGS, Riberiro ACM, Moraes JCB, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012;14:R216.
25. Lories RJU, Dougados M. Inflammation and ankylosis: still an enigmatic relationship in spondyloarthritis. Ann Rheum Dis 2012;71:317-18.
26. Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012;64:1713-19.
27. Urshansky N, Mausner-Fainberg K, Auriel E, et al. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2011;232:171-8.
28. van Schaik FDM, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013;62:683-8.
29. Cua DJ, Sherlock JP. Gut microbiota strikes 'back'. Nat Med 2011;17:1055-6.
30. Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012;343:364-6.
31. Sieper J. How to screen for axial spondyloarthritis in primary care? Curr Opin Rheumatol 2012;24:359-62.